<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEMTRADA- alemtuzumab injection, solution, concentrate </strong><br>Genzyme Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LEMTRADA safely and effectively. See full prescribing information for LEMTRADA. <br><br>LEMTRADA™ (alemtuzumab) injection, for intravenous use <br>Initial U.S. Approval: 2001</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: AUTOIMMUNITY, INFUSION REACTIONS, AND MALIGNANCIES</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine counts at periodic intervals for 48 months after the last dose. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">LEMTRADA causes serious and life-threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2 hour monitoring period. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Perform baseline and yearly skin exams. (<a href="#S5.3">5.3</a>)</span></li>
<li><span class="Bold">LEMTRADA is available only through a restricted distribution program. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: AUTOIMMUNITY, INFUSION REACTIONS, AND MALIGNANCIES</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine counts at periodic intervals for 48 months after the last dose. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">LEMTRADA causes serious and life-threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2 hour monitoring period. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold">LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Perform baseline and yearly skin exams. (<a href="#S5.3">5.3</a>)</span></li>
<li><span class="Bold">LEMTRADA is available only through a restricted distribution program. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul><li>LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of patients with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS). Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. (<a href="#S1">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer LEMTRADA by intravenous infusion over 4 hours for 2 treatment courses:<ul class="Circle">
<li>First course: 12 mg/day on 5 consecutive days. (<a href="#S2.1">2.1</a>)</li>
<li>Second course: 12 mg/day on 3 consecutive days 12 months after first treatment course. (<a href="#S2.1">2.1</a>)</li>
</ul>
</li>
<li>Premedicate with corticosteroids prior to LEMTRADA infusion for the first 3 days of each treatment course. (<a href="#S2.3">2.3</a>)</li>
<li>Administer antiviral agents for herpetic prophylaxis starting on the first day of LEMTRADA dosing and continuing for a minimum of two months after completion of LEMTRADA dosing or until CD4+ lymphocyte count is more than 200 cells per microliter, whichever occurs later. (<a href="#S2.3">2.3</a>)</li>
<li>Must be diluted prior to administration. (<a href="#S2.4">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection: 12 mg/1.2 mL (10 mg/mL) in a single-use vial. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span>: Obtain <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> prior to initiation of treatment and every 3 months until 48 months after the last infusion. (<a href="#S5.7">5.7</a>)</li>
<li>Other Autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span>: Monitor complete blood counts monthly until 48 months after the last infusion. (<a href="#S5.8">5.8</a>)</li>
<li>Consider delaying initiation of LEMTRADA in patients with active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is fully controlled. Do not administer live viral vaccines following a course of LEMTRADA. (<a href="#S5.9">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥ 10% and &gt; interferon beta-1a): <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infection</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, thyroid gland disorders, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 (option 2) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>) </p></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: AUTOIMMUNITY, INFUSION REACTIONS, AND MALIGNANCIES</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Vaccinations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Recommended Premedication and Concomitant Medication</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation Instructions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Infusion Instructions</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Laboratory Testing and Monitoring to Assess Safety</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Autoimmunity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Infusion Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Malignancies</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 LEMTRADA REMS Program</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Glomerular Nephropathies</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Other Autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Drug Products with Same Active Ingredient</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3  <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> or Ideation</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Immunogenicity</a></h2>
<h2><a href="#section-6.5" class="toc">6.5  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: AUTOIMMUNITY, INFUSION REACTIONS, AND MALIGNANCIES</span></h1>
<ul>
<li><span class="Bold">LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts at periodic intervals for 48 months after the last dose of LEMTRADA <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li><span class="Bold">LEMTRADA causes serious and life threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. </span></li>
<li><span class="Bold">LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>. Perform baseline and yearly skin exams <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</span></li>
<li><span class="Bold">Because of the risk of autoimmunity, infusion reactions, and malignancies, LEMTRADA is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the LEMTRADA REMS program <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>. </span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LEMTRADA is indicated for the treatment of patients with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS). Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage Information</h2>
<p class="First">The recommended dosage of LEMTRADA is 12 mg/day administered by intravenous infusion for 2 treatment courses:</p>
<ul class="Disc">
<li>First Treatment Course: 12 mg/day on 5 consecutive days (60 mg total dose)</li>
<li>Second Treatment Course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Vaccinations</h2>
<p class="First">Patients should complete any necessary immunizations at least 6 weeks prior to treatment with LEMTRADA <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Prior to LEMTRADA treatment determine whether patients have a history of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> or have been vaccinated for <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV). If not, test the patient for antibodies to VZV and consider vaccination for those who are antibody-negative. Postpone treatment with LEMTRADA until 6 weeks after VZV vaccination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Recommended Premedication and Concomitant Medication</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Underline">Corticosteroids</span></p>
<p>Premedicate patients with high dose corticosteroids (1,000 mg methylprednisolone or equivalent) immediately prior to LEMTRADA infusion and for the first 3 days of each treatment course <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Underline">Herpes Prophylaxis</span></p>
<p>Administer anti-viral prophylaxis for herpetic <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> starting on the first day of each treatment course and continue for a minimum of two months following treatment with LEMTRADA or until the CD4+ lymphocyte count is ≥ 200 cells per microliter, whichever occurs later <span class="Italics">[</span>see <span class="Italics"><a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation Instructions</h2>
<p class="First">Follow the steps below to prepare the diluted solution of LEMTRADA for intravenous infusion:</p>
<ul class="Disc">
<li>Inspect LEMTRADA visually for particulate matter and discoloration prior to administration. Do not use if particulate matter is present or the solution is discolored. Do not freeze or shake vials prior to use.</li>
<li>Withdraw 1.2 mL of LEMTRADA from the vial into a syringe using aseptic technique and inject into a 100 mL bag of sterile 0.9% Sodium Chloride, USP or 5% Dextrose in Water, USP.</li>
<li>Gently invert the bag to mix the solution. Ensure the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the prepared solution, because it contains no antimicrobial preservatives. Each vial is for single use only.</li>
</ul>
<p>Prior to administration, protect diluted LEMTRADA solution from light and store for as long as 8 hours either at room temperature 15°C to 25°C (59°F to 77°F) or keep refrigerated at conditions 2°C to 8°C (36°F to 46°F). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Infusion Instructions</h2>
<p class="First">Infuse LEMTRADA over 4 hours starting within 8 hours after dilution. Extend the duration of the infusion if clinically indicated.</p>
<p>Administer LEMTRADA in a setting in which equipment and personnel to appropriately manage <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or serious infusion reactions are available <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>. </p>
<p>Do not add or simultaneously infuse other drug substances through the same intravenous line. Do not administer as an intravenous push or bolus.</p>
<p>Monitor vital signs before the infusion and periodically during the infusion. Provide appropriate symptomatic treatment for infusion reactions as needed. Consider immediate discontinuation of the intravenous infusion if severe infusion reactions occur.</p>
<p>Observe patients for infusion reactions during and for at least 2 hours after each LEMTRADA infusion. Consider longer periods of observation if clinically indicated. Inform patients that they should report symptoms that occur during and after each infusion because they may indicate a need for prompt medical intervention <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Laboratory Testing and Monitoring to Assess Safety</h2>
<p class="First">Conduct the following laboratory tests at baseline and at periodic intervals for 48 months following the last treatment course of LEMTRADA in order to monitor for early signs of potentially serious adverse effects:</p>
<ul class="Disc">
<li>Complete blood count (CBC) with differential (prior to treatment initiation and at monthly intervals thereafter)</li>
<li>Serum creatinine levels (prior to treatment initiation and at monthly intervals thereafter)</li>
<li>Urinalysis with urine cell counts (prior to treatment initiation and at monthly intervals thereafter)</li>
<li>A test of thyroid function, such as thyroid stimulating hormone (TSH) level (prior to treatment initiation and every 3 months thereafter)</li>
</ul>
<p>Conduct baseline and yearly skin exams to monitor for melanoma <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection: 12 mg/1.2 mL (10 mg/mL) in a single-use vial. LEMTRADA is a clear and colorless to slightly yellow solution that requires dilution prior to intravenous infusion.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LEMTRADA is contraindicated in patients who are infected with Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV) because LEMTRADA causes prolonged reductions of CD4+ lymphocyte counts.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Autoimmunity</h2>
<p class="First">Treatment with LEMTRADA can result in the formation of autoantibodies and increase the risk of serious autoimmune mediated conditions. In clinical studies LEMTRADA-treated patients experienced <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> (34%), immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (2%), and glomerular nephropathies (0.3%) <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5</a>, <a href="#S5.6">5.6</a>, <a href="#S5.7">5.7)</a>]</span>. <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">Autoimmune hemolytic anemia</span> and autoimmune <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>, undifferentiated <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>, and acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (anti-Factor VIII antibodies) each occurred in 0.2% of patients. <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, type I <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">vitiligo</span>, and <span class="product-label-link" type="condition" conceptid="438744" conceptname="Acute posterior multifocal placoid pigment epitheliopathy">retinal pigment epitheliopathy</span> occurred in 0.1% of patients.</p>
<p>During postmarketing use, additional autoimmune events including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy have been reported in the treatment of patients with B-cell <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (B-CLL), as well as other disorders, generally at higher and more frequent doses than recommended in MS. An oncology patient treated with alemtuzumab had fatal transfusion-associated graft-versus-host disease.</p>
<p>Autoantibodies may be transferred from the mother to the fetus during pregnancy. A case of transplacental transfer of anti-thyrotropin receptor antibodies resulting in neonatal Graves' disease occurred after alemtuzumab treatment in the mother <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>LEMTRADA may increase the risk of other autoimmune conditions because of the broad range of autoantibody formation with LEMTRADA.</p>
<p>Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts before starting treatment and then at monthly intervals for 48 months after the last dose of LEMTRADA to allow for early detection and treatment of autoimmune adverse reactions <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>]</span>. After 48 months, testing should be performed based on clinical findings suggestive of autoimmunity.</p>
<p>LEMTRADA is available only through a restricted program under a REMS <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Infusion Reactions</h2>
<p class="First">LEMTRADA causes cytokine release syndrome resulting in infusion reactions, some of which may be serious and life threatening. In clinical studies, 92% of LEMTRADA-treated patients experienced infusion reactions. In some patients, infusion reactions were reported more than 24 hours after LEMTRADA infusion. Serious reactions occurred in 3% of patients and included <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> in 2 patients (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>), <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), transient <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Other infusion reactions included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In clinical studies, 0.6% of patients with infusion reactions received epinephrine or atropine.</p>
<p>During postmarketing use, other serious and sometimes fatal infusion reactions included <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">acute cardiac insufficiency</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have been reported in the treatment of patients with B-CLL, as well as other disorders, generally at higher and more frequent doses than recommended in MS.</p>
<p>Premedicate patients with corticosteroids immediately prior to LEMTRADA infusion for the first 3 days of each treatment course. In clinical trials, patients received 1,000 mg of methylprednisolone for the first 3 days of each LEMTRADA treatment course. Consider pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration. Infusion reactions may occur despite pretreatment.</p>
<p>Consider additional monitoring in patients with medical conditions which predispose them to cardiovascular or pulmonary compromise.</p>
<p>LEMTRADA can only be administered in certified healthcare settings that have on-site access to equipment and personnel trained to manage infusion reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and cardiac and respiratory emergencies). </p>
<p>LEMTRADA is available only through a restricted program under a REMS <span class="Italics">[see <a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Malignancies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Underline">Thyroid cancer</span></p>
<p>LEMTRADA may increase the risk of thyroid cancer. In controlled clinical studies, 3 of 919 (0.3%) LEMTRADA-treated patients developed thyroid cancer, compared to none in the interferon beta-1a-treated group. However, screening for thyroid cancer was performed more frequently in the LEMTRADA-treated group, because of the higher incidence of autoimmune <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> in those patients. Two additional cases of thyroid cancer in LEMTRADA-treated patients occurred in uncontrolled studies.</p>
<p>Patients and healthcare providers should monitor for symptoms of thyroid cancer including a new lump or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the neck, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the front of the neck, persistent <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span> or other voice changes, trouble swallowing or breathing, or a constant <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> not due to an <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First"><span class="Underline">Melanoma</span></p>
<p>LEMTRADA may increase the risk of melanoma. In uncontrolled studies, 4 of 1486 (0.3%) LEMTRADA-treated patients developed melanoma or melanoma <span class="Italics">in situ</span>. One of those patients had evidence of locally advanced disease.</p>
<p>Perform baseline and yearly skin examinations to monitor for melanoma in patients receiving LEMTRADA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative disorders</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span></span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> have occurred in LEMTRADA-treated patients with MS, including a <span class="product-label-link" type="condition" conceptid="4028704" conceptname="Marginal zone B-cell lymphoma">MALT lymphoma</span>, Castleman's Disease, and a fatality following treatment of non-Epstein Barr Virus-associated Burkitt's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. There are postmarketing reports of Epstein Barr Virus-associated <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> in non-MS patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.4"></a><p></p>
<p class="First">Because LEMTRADA is an immunomodulatory therapy, caution should also be exercised in initiating LEMTRADA in patients with pre-existing or ongoing malignancies.</p>
<p>LEMTRADA is available only through a restricted program under a REMS <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 LEMTRADA REMS Program</h2>
<p class="First">LEMTRADA is available only through a restricted program under a REMS called the LEMTRADA REMS Program, because of the risks of autoimmunity, infusion reactions, and malignancies <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3)</a>]</span>. </p>
<p>Notable requirements of the LEMTRADA REMS Program include the following:</p>
<ul class="Disc">
<li>Prescribers must be certified with the program by enrolling and completing training.</li>
<li>Patients must enroll in the program and comply with ongoing monitoring requirements <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>]</span>.</li>
<li>Pharmacies must be certified with the program and must only dispense to certified healthcare facilities that are authorized to receive LEMTRADA.</li>
<li>Healthcare facilities must enroll in the program and verify that patients are authorized before infusing LEMTRADA. Healthcare facilities must have on-site access to equipment and personnel trained to manage infusion reactions.</li>
</ul>
<p>Further information, including a list of qualified healthcare facilities, is available at 1-855-676-6326.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First">Immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (ITP) occurred in 2% of LEMTRADA-treated patients in clinical studies in MS. </p>
<p>In a controlled clinical trial in patients with MS, one LEMTRADA-treated patient developed ITP that went unrecognized prior to the implementation of monthly blood monitoring requirements, and died from <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhage</span>. Nadir platelet counts ≤20,000 cells per microliter as a result of ITP occurred in 2% of all LEMTRADA-treated patients in clinical studies in MS. Anti-platelet antibodies did not precede ITP onset. ITP has been diagnosed more than 3 years after the last LEMTRADA dose.</p>
<p>Symptoms of ITP include easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, spontaneous mucocutaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (e.g., <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>), and heavier than normal or irregular menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span> may also be indicative of anti-glomerular basement membrane (GBM) disease <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>, and an appropriate differential diagnosis has to be undertaken. Remind the patient to remain vigilant for symptoms they may experience and to seek immediate medical help if they have any concerns.</p>
<p>Obtain complete blood counts (CBCs) with differential prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>]</span>. After this period of time, testing should be performed based on clinical findings suggestive of ITP. If ITP is suspected, a complete blood count should be obtained immediately. If ITP onset is confirmed, promptly initiate appropriate medical intervention. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Glomerular Nephropathies</h2>
<p class="First">Glomerular nephropathies occurred in 0.3% of LEMTRADA-treated patients in MS clinical trials. There were 3 cases of membranous <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span> and 2 cases of anti-glomerular basement membrane (anti-GBM) disease. There are published and post-marketing cases of MS patients treated with alemtuzumab who developed anti-GBM disease and subsequently developed end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring renal transplantation. Cases of anti-GBM disease have been diagnosed up to 40 months after the last dose of LEMTRADA. Urgent evaluation and treatment is required because anti-GBM disease can lead to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> requiring dialysis or transplantation and can be life-threatening if left untreated.</p>
<p>Clinical manifestations of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> may include elevated serum creatinine levels, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. Alveolar <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> manifested as <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> is a common component of anti-GBM disease but did not occur in clinical trials.</p>
<p>Obtain serum creatinine levels and urinalysis with cell counts prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion. After this period of time, testing should be performed based on clinical findings suggestive of nephropathies.</p>
<p>If clinically significant changes from baseline in serum creatinine, unexplained <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> are observed, perform further evaluation for nephropathies. Early detection and treatment of nephropathies may decrease the risk of poor outcomes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span></h2>
<p class="First">Autoimmune <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> occurred in 34% of LEMTRADA-treated patients in clinical studies. Newly diagnosed <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> occurred throughout the uncontrolled clinical study follow-up period, more than 7 years after the first LEMTRADA dose. Autoimmune <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> included Graves' disease, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. Graves' ophthalmopathy with decreased vision, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, and <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span> occurred in 1% of LEMTRADA-treated patients. Two patients required surgical orbital decompression. Serious thyroid events occurred in about 2% of LEMTRADA-treated patients in clinical studies and included cardiac and psychiatric events associated with thyroid disease. Of all LEMTRADA-treated patients, 3% underwent thyroidectomy. </p>
<p>Thyroid disease poses special risks in women who are pregnant <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>Obtain <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span>, such as TSH levels, prior to initiation of treatment and every 3 months thereafter until 48 months after the last infusion. Continue to test thyroid function after 48 months if clinically indicated. </p>
<p>In patients with ongoing <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorder</span>, LEMTRADA should be administered only if the potential benefit justifies the potential risks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Other Autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></h2>
<p class="First">Autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> such as <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (0.1%), <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> (0.2%), and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (0.2%) occurred in LEMTRADA-treated patients in clinical studies in MS. In cases of <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span>, patients tested positive for direct antiglobulin antibodies, and nadir hemoglobin levels ranged from 2.9-8.6 g/dL. Symptoms of <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span> include <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. One LEMTRADA-treated patient with autoimmune <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> died from <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p>During postmarketing use, additional autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> including fatal <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in the treatment of patients with B-CLL, as well as other disorders, generally at higher and more frequent doses than recommended in MS. </p>
<p>Use CBC results to monitor for <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>. Prompt medical intervention is indicated if a <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> is confirmed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> occurred in 71% of LEMTRADA-treated patients compared to 53% of patients treated with interferon beta-1a in controlled clinical trials in MS up to 2 years in duration. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> that occurred more often in LEMTRADA-treated patients than interferon beta-1a patients included <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, herpetic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, and <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> occurred in 3% of patients treated with LEMTRADA as compared to 1% of patients treated with interferon beta-1a. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the LEMTRADA group included: <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, and <span class="product-label-link" type="condition" conceptid="4322737" conceptname="Infection of tooth">tooth infection</span>. </p>
<p>Do not administer live viral vaccines following a course of LEMTRADA. Patients treated with LEMTRADA have altered immunity and may be at increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following administration of live viral vaccines.</p>
<p>Consider delaying LEMTRADA administration in patients with active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is fully controlled.</p>
<p>Concomitant use of LEMTRADA with antineoplastic or immunosuppressive therapies could increase the risk of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">Herpes Viral Infections</span></span></p>
<p>In controlled clinical trials, 16% of LEMTRADA-treated patients developed a <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infection</span> compared to 3% of interferon beta-1a patients. These events included <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">oral herpes</span> (8.8%), <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (4.2%), herpes simplex (1.8%), and <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> (1.3%). Serious herpetic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in LEMTRADA-treated patients included primary <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> (0.1%), <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (0.2%), and herpes <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> (0.1%). Administer antiviral agents for herpetic prophylaxis at appropriate suppressive dosing regimens. Administer anti-viral prophylaxis for herpetic <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> starting on the first day of each treatment course and continue for a minimum of two months following treatment with LEMTRADA or until the CD4+ lymphocyte count is ≥ 200 cells per microliter, whichever occurs later <span class="Italics">[</span>see <span class="Italics"><a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.2"></a><p></p>
<p class="First"><span class="Underline">Human <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">Papilloma</span> Virus</span></p>
<p>Cervical human <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> virus (HPV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="192367" conceptname="Dysplasia of cervix">cervical dysplasia</span>, occurred in 2% of LEMTRADA-treated patients. Annual HPV screening is recommended for female patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> occurred in patients treated with LEMTRADA and interferon beta-1a in controlled clinical trials. Active and latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> cases occurred in 0.3% of LEMTRADA-treated patients, most often in endemic regions. Perform <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> screening according to local guidelines prior to initiation of LEMTRADA. For patients testing positive in <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> screening, treat by standard medical practice prior to therapy with LEMTRADA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span>, especially oral and <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, occurred more commonly in LEMTRADA-treated patients (12%) than in patients treated with interferon beta-1a (3%) in controlled clinical trials in MS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.5"></a><p></p>
<p class="First"><span class="Underline">Listeria <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>Listeria <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> has been reported in LEMTRADA-treated patients. Cases of listeria <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> occurred within 1 month of alemtuzumab dosing. The duration of increased risk for listeria <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> is unclear. Patients should avoid or adequately heat foods that are potential sources of <span class="Italics">Listeria monocytogenes. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.6"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in non-MS patients</span></p>
<p>During postmarketing use, serious and sometimes fatal viral, bacterial, protozoan, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, including some due to reactivation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, have been reported in the treatment of patients with B-CLL, as well as other disorders, generally at higher and more frequent doses than recommended in MS. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.7"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></span></p>
<p>No data are available on the association of LEMTRADA with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B virus (HBV) or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus (HCV) reactivation because patients with evidence of active or chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were excluded from the clinical trials. Consider screening patients at high risk of HBV and/or HCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before initiation of LEMTRADA and exercise caution in prescribing LEMTRADA to patients identified as carriers of HBV and/or HCV as these patients may be at risk of irreversible <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> relative to a potential virus reactivation as a consequence of their pre-existing status.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></h2>
<p class="First">In clinical studies, 6 of 1217 (0.5%) LEMTRADA-treated patients had <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> of varying severity. Cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> with <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> occurred in clinical studies. Patients should be advised to report symptoms of <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, which include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or tightness, and <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Drug Products with Same Active Ingredient</h2>
<p class="First">LEMTRADA contains the same active ingredient (alemtuzumab) found in CAMPATH<span class="Sup">®</span>. If LEMTRADA is considered for use in a patient who has previously received CAMPATH, exercise increased vigilance for additive and long-lasting effects on the immune system. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:</p>
<ul class="Disc">
<li>Autoimmunity <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Infusion reactions <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Malignancies <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Glomerular Nephropathies <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorder</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Other Autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span> <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In controlled clinical trials (Study 1 and Study 2), a total of 811 patients with relapsing forms of MS received LEMTRADA. A total of 811 patients received 1 course of therapy, and 789 patients received a second course of therapy at 12 months. The overall follow-up in the controlled trials was equivalent to 1622 patient years, with an additional 3411 person-years of follow-up in an open label extension study. The population was 18-55 years of age, 65% were female, and 92% were Caucasian. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Most Common Adverse Reactions</span></p>
<p>In clinical trials, the most common adverse reactions with LEMTRADA (in at least 10% of patients and more frequently than in interferon beta-1a) were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infection</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, thyroid gland disorders, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>Table 1 lists adverse reactions occurring in ≥5% of LEMTRADA-treated patients in Study 1 and 2 and at the same or at a higher rate than interferon beta-1a.</p>
<table width="80%">
<caption><span>Table 1: Adverse Reactions in the Pooled 2-Year Active-Controlled Studies in Patients with Relapsing-Remitting <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></span></caption>
<col align="left" valign="top" width="37%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="top">LEMTRADA<br>(N=811) <br>%</th>
<th class="Rrule" align="center" valign="top">interferon beta-1a 44 mcg<br>(N=389)<br>%</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">23</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">Herpes viral infection</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Thyroid gland disorders</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">Blood in urine</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Decrease in CD4 <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Decrease in CD8 <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Decrease in T-lymphocyte count</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck Pain</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></h2>
<p class="First">Nearly all (99.9%) patients treated with LEMTRADA in MS clinical trials experienced <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>. The lowest lymphocyte counts occurred approximately by 1 month after each course of treatment. The mean lymphocyte count at 1 month after LEMTRADA treatment was 0.25 × 10<span class="Sup">9</span>L (range 0.02-2.30 × 10<span class="Sup">9</span>L) and 0.32 (0.02-1.81 × 10<span class="Sup">9</span>L) for treatment courses 1 and 2, respectively. Total lymphocyte counts increased to reach the lower limit of normal in approximately 40% of patients by 6 months after each LEMTRADA treatment course and approximately 80% of patients by 12 months after each course <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3  <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> or Ideation</h2>
<p class="First">In clinical studies, 0.6% of patients in both the LEMTRADA and interferon beta-1a groups had events of <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>. There were no <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span> in either clinical study treatment group. <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> or ideation occurred in patients with or without a history of a psychiatric or <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorder</span>. Advise patients to report immediately any symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> to the prescribing physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. Using an enzyme-linked immunosorbent assay (ELISA) and a competitive binding assay, anti-alemtuzumab binding antibodies were detected in 62%, 67%, and 29% of LEMTRADA-treated patients, at months 1, 3, 12 (Course 1) as well as 83%, 83%, and 75% of LEMTRADA-treated patients at months 13, 15, and 24 (Course 2). Samples that tested positive for binding antibodies were further evaluated for evidence of <span class="Italics">in vitro</span> inhibition using a <span class="product-label-link" type="condition" conceptid="45769412" conceptname="Flow cytometry">flow cytometry</span> assay. Neutralizing antibodies were detected in 87%, 46%, and 5% of positive binding antibody patients at months 1, 3, 12 (Course 1) as well as 94%, 88%, and 42% of positive binding antibody patients at months 13, 15, and 24 (Course 2). Anti-alemtuzumab antibodies were associated with decreased alemtuzumab concentration during Course 2 but not Course 1. There was no evidence from clinical trials that the presence of binding or inhibitory anti-alemtuzumab antibodies had a significant effect on clinical outcomes, total lymphocyte count, or adverse events. </p>
<p>The incidence of antibodies is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including inhibitory antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to LEMTRADA with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.5"></a><a name="section-6.5"></a><p></p>
<h2>6.5  Postmarketing Experience</h2>
<p class="First">The following adverse reactions, not described elsewhere, were identified during post-approval use of alemtuzumab (CAMPATH) for the treatment of B-cell <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (B-CLL), as well as for the treatment of other disorders, generally at higher and more frequent doses (e.g., 30 mg) than that recommended in the treatment of MS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, and decreased <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> in non-MS patients previously treated with potentially cardiotoxic agents.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies in pregnant women. LEMTRADA was embryolethal in pregnant huCD52 transgenic mice when administered during organogenesis. Auto-antibodies may develop after administration of LEMTRADA. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves' disease has been reported. LEMTRADA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1.1"></a><p></p>
<p class="First"><span class="Underline">Animal Data</span></p>
<p>When LEMTRADA was administered to pregnant huCD52 transgenic mice during organogenesis (gestation days [GD] 6-10 or GD 11-15) at doses of 3 or 10 mg/kg IV, no teratogenic effects were observed. However, there was an increase in embryolethality (increased post-implantation loss and the number of dams with all fetuses dead or resorbed) in pregnant animals dosed during GD 11-15.</p>
<p>In a separate study in pregnant huCD52 transgenic mice, administration of LEMTRADA during organogenesis (GD 6-10 or GD 11-15) at doses of 3 or 10 mg/kg/IV, decreases in B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and T-lymphocyte populations were observed in the offspring at both doses tested. The effects of LEMTRADA, administered during organogenesis, on postnatal development have not been adequately assessed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1.2"></a><p></p>
<p class="First"><span class="Underline">Clinical Considerations </span></p>
<p>To avoid in utero exposure to LEMTRADA, women of child bearing potential should use effective contraceptive measures when receiving a course of treatment with LEMTRADA and for 4 months following that course of treatment.</p>
<p>LEMTRADA induces persistent <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>. Untreated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> in pregnant women increases the risk for <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and may have effects on the fetus including <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span> and <span class="product-label-link" type="condition" conceptid="25780" conceptname="Pituitary dwarfism">dwarfism</span>. In mothers with Graves' disease, maternal thyroid stimulating hormone receptor antibodies can be transferred to a developing fetus and can cause neonatal Graves' disease. In a patient who developed Graves' disease after treatment with alemtuzumab, placental transfer of anti-thyrotropin receptor antibodies resulted in neonatal Graves' Disease with <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span> in her infant who was born 1 year after alemtuzumab dosing <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Alemtuzumab was detected in the milk of lactating mice administered 10 mg/kg LEMTRADA on Days 8 through 12 postpartum. Serum levels of alemtuzumab were similar in lactating mice and offspring on Day 13 postpartum, and were associated with evidence of pharmacological activity (decrease in lymphocyte counts) in the offspring. </p>
<p>It is not known whether alemtuzumab is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from LEMTRADA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity, infusion reactions, and because it may increase the risk of malignancies (thyroid, melanoma, <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span>, and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>) <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of LEMTRADA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-8"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Two MS patients experienced serious reactions (<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and either <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>) after a single accidental infusion up to 60 mg of LEMTRADA. Doses of LEMTRADA greater than those recommended may increase the intensity and/or duration of infusion reactions or its immune effects. There is no known antidote for alemtuzumab overdosage. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LEMTRADA (alemtuzumab) is a recombinant humanized IgG1 kappa monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab has an approximate molecular weight of 150kD. LEMTRADA is produced in mammalian cell (Chinese hamster ovary) suspension culture in a nutrient medium containing neomycin. Neomycin is not detectable in the final product. LEMTRADA is a sterile, clear and colorless to slightly yellow, solution (pH 7.2±0.2) for infusion.</p>
<p>Each 1 mL of solution contains alemtuzumab 10 mg, dibasic sodium phosphate (1.15 mg), disodium edetate dihydrate (0.0187 mg), polysorbate 80 (0.1 mg), potassium chloride (0.2 mg), potassium dihydrogen phosphate (0.2 mg), sodium chloride (8 mg), and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanism by which alemtuzumab exerts its therapeutic effects in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> is unknown but is presumed to involve binding to CD52, a cell surface antigen present on T and B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and on natural killer cells, monocytes, and macrophages. Following cell surface binding to T and B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, alemtuzumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Underline">Effects of LEMTRADA on the Lymphocyte Population</span></p>
<p>LEMTRADA depletes circulating T and B <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> after each treatment course. In clinical trials, the lowest cell counts occurred 1 month after a course of treatment at the time of the first post-treatment blood count. Lymphocyte counts then increased over time: B cell counts usually recovered within 6 months; T cell counts increased more slowly and usually remained below baseline 12 months after treatment. Approximately 60% of patients had total lymphocyte counts below the lower limit of normal 6 months after each treatment course and 20% had counts below the lower limit of normal after 12 months.</p>
<p>Reconstitution of the lymphocyte population varies for the different lymphocyte subtypes. At Month 1 in clinical trials, the mean CD4+ lymphocyte count was 40 cells per microliter, and, at Month 12, 270 cells per microliter. At 30 months, approximately half of patients had CD4+ lymphocyte counts that remained below the lower limit of normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<p class="First"><span class="Underline">Cardiac Electrophysiology</span></p>
<p>In a study of 53 MS patients, alemtuzumab 12 mg per day for 5 days caused no changes in the QTc interval greater than 20ms. An average 22 to 26 beats-per-minute increase in heart rate was observed for at least 2 hours after the first but not subsequent infusions.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of LEMTRADA were evaluated in a total of 148 patients with relapsing forms of MS who received 12 mg/day on 5 consecutive days, followed by 12 mg/day on 3 consecutive days 12 months following the first treatment course. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Serum concentrations increased with each consecutive dose within a treatment course, with the highest observed concentrations occurring following the last infusion of a treatment course. The mean maximum concentration was 3014 ng/mL on Day 5 of the first treatment course, and 2276 ng/mL on Day 3 of the second treatment course. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>LEMTRADA is largely confined to the blood and interstitial space with a central volume of distribution of 14.1 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.3"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>The elimination half-life was approximately 2 weeks and was comparable between courses. The serum concentrations were generally undetectable (&lt; 60 ng/mL) within approximately 30 days following each treatment course.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
<p>Age, race, or gender had no effect on the pharmacokinetics of LEMTRADA.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies to assess the carcinogenic or genotoxic potential of LEMTRADA have not been conducted.</p>
<p>When LEMTRADA (3 or 10 mg/kg IV) was administered to huCD52 transgenic male mice on 5 consecutive days prior to cohabitation with untreated wild-type females, no effect on fertility or reproductive performance was observed. However, adverse effects on sperm parameters (including abnormal morphology [<span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span> /no head] and reduced total count and motility) were observed at both doses tested.</p>
<p>When LEMTRADA (3 or 10 mg/kg IV) was administered to huCD52 transgenic female mice for 5 consecutive days prior to cohabitation with untreated wild-type males, there was a decrease in the average number of corpora lutea and implantation sites and an increase in post-implantation loss, resulting in fewer viable embryos at the higher dose tested. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of LEMTRADA was demonstrated in two studies (Study 1 and 2) that evaluated LEMTRADA 12 mg in patients with relapsing-remitting <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (RRMS). LEMTRADA was administered by intravenous infusion once daily over a 5-day course, followed one year later by intravenous infusion once daily over a 3-day course. Both studies included patients who had experienced at least 2 relapses during the 2 years prior to trial entry and at least 1 relapse during the year prior to trial entry. Neurological examinations were performed every 12 weeks and at the time of suspected relapse. Magnetic resonance imaging (MRI) evaluations were performed annually. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Underline">Study 1</span></p>
<p>Study 1 was a 2 year randomized, open-label, rater-blinded, active comparator (interferon beta-1a 44 micrograms administered subcutaneously three times a week) controlled study in patients with RRMS. Patients entering Study 1 had Expanded <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Status Scale (EDSS) scores of 5 or less and had to have experienced at least one relapse while on interferon beta or glatiramer acetate therapy. </p>
<p>Patients were randomized to receive LEMTRADA (n=426) or interferon beta-1a (n=202). At baseline, the mean age was 35 years, the mean disease duration was 4.5 years, and the mean EDSS score was 2.7. </p>
<p>The clinical outcome measures were the annualized relapse rate (ARR) over 2 years and the time to confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression. Confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression was defined as at least a 1 point increase above baseline EDSS (1.5 point increase for patients with baseline EDSS of 0) sustained for 6 months. The MRI outcome measure was the change in T2 lesion volume.</p>
<p>The annualized relapse rate was significantly lower in patients treated with LEMTRADA than in patients who received interferon beta-1a. Time to onset of 6-month confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression was significantly delayed with LEMTRADA treatment compared to interferon beta-1a. There was no significant difference between the treatment groups for the change in T2 lesion volume. The results of Study 1 are shown in Table 2 and Figure 1. </p>
<table width="100%">
<caption><span>Table 2: Clinical and MRI Results of Study 1</span></caption>
<col align="left" valign="top" width="45%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" valign="bottom">LEMTRADA<br>(N=426)</th>
<th class="Botrule Rrule" align="center">interferon beta-1a 44 mcg<br>(N=202)</th>
<th class="Botrule Rrule" align="center">p-value</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Clinical Outcomes</span></td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Annualized relapse rate<br>  Relative reduction</td>
<td class="Botrule Rrule" align="center">0.26<br>49%</td>
<td class="Botrule Rrule" align="center">0.52</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Proportion of patients with <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression at Year 2<br>  Relative risk reduction</td>
<td class="Botrule Rrule" align="center">13%<br>42%</td>
<td class="Botrule Rrule" align="center">21%</td>
<td class="Botrule Rrule" align="center">0.0084</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Percent of patients remaining relapse-free at Year 2</td>
<td class="Botrule Rrule" align="center">65%</td>
<td class="Botrule Rrule" align="center">47%</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">MRI Outcomes</span></td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Percent change in T2 lesion volume from baseline</td>
<td class="Botrule Rrule" align="center">-1.3</td>
<td class="Botrule Rrule" align="center">-1.2</td>
<td class="Botrule Rrule" align="center">0.14</td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<colgroup><col align="left" valign="top" width="100%"></colgroup>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 1: Time to 6-month Confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Progression (Study 1)</span></td></tr>
<tr><td align="left"><p class="First"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269&amp;name=lemtrada-01.jpg"></p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<p class="First"><span class="Underline">Study 2</span></p>
<p>Study 2 was a 2-year randomized, open-label, rater-blinded, active comparator (interferon beta-1a 44 micrograms administered subcutaneously three times a week) controlled study in patients with RRMS. Patients entering Study 2 had EDSS scores of 3 or less and no prior treatment for <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. </p>
<p>Patients were randomized to receive LEMTRADA (n=376) or interferon beta-1a (n=187). At baseline, the mean age was 33 years, the mean disease duration was 2 years, and the mean EDSS score was 2. </p>
<p>The clinical outcome measures were the annualized relapse rate (ARR) over 2 years and the time to confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression, as defined in Study 1. The MRI outcome measure was the change in T2 lesion volume.</p>
<p>The annualized relapse rate was significantly lower in patients treated with LEMTRADA than in patients who received interferon beta-1a. There was no significant difference between the treatment groups for the time to confirmed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression and for the primary MRI endpoint (change in T2 lesion volume). The results for Study 2 are shown in Table 3. </p>
<table width="100%">
<caption><span>Table 3: Clinical and MRI Results of Study 2</span></caption>
<col align="left" valign="top" width="45%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">LEMTRADA</th>
<th class="Rrule" align="center">interferon beta-1a 44 mcg</th>
<th class="Rrule" align="center">p-value</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="bottom">(N=376)</th>
<th class="Rrule" align="center">(N=187)</th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Clinical Outcomes</span></td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Annualized relapse rate<br>  Relative reduction</td>
<td class="Rrule" align="center">0.18<br>55%</td>
<td class="Rrule" align="center">0.39</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Proportion of patients with <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> progression at Year 2<br>  Relative risk reduction</td>
<td class="Rrule" align="center">8%<br>30%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">0.22</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Percent of patients remaining relapse-free at Year 2</td>
<td class="Rrule" align="center">78%</td>
<td class="Rrule" align="center">59%</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">MRI Outcomes</span></td>
<td class="Botrule Rrule" align="center"> </td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Percent change in T2 lesion volume from baseline</td>
<td class="Rrule" align="center">-9.3</td>
<td class="Rrule" align="center">-6.5</td>
<td class="Rrule" align="center">0.31</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Each LEMTRADA carton (NDC: 58468-0200-1) contains 1 single-use vial that delivers 12 mg/1.2 mL (10 mg/mL). The vial stopper is not made with natural rubber latex.</p>
<p>LEMTRADA is a sterile, clear and colorless to slightly yellow solution for infusion, containing no antimicrobial preservatives. </p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store LEMTRADA vials at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Store in original carton to protect from light. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Underline">Autoimmunity</span></p>
<ul>
<li>Advise patients to contact their healthcare provider promptly if they experience any symptoms of potential autoimmune disease. Give examples of important symptoms such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. </li>
<li>Advise patients of the importance of monthly blood and urine tests for 48 months following the last course of LEMTRADA to monitor for signs of autoimmunity because early detection and prompt treatment can help prevent serious and potentially fatal outcomes associated with these events. Advise patients that monitoring may need to continue past 48 months if they have signs or symptoms of autoimmunity.</li>
<li>Advise patients that LEMTRADA may cause hyperthyroid or hypothyroid disorders. </li>
<li>Advise patients to contact their healthcare provider if they experience symptoms reflective of a potential <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorder</span> such as unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> or gain, fast heartbeat or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, or <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span>.</li>
<li>Advise women of childbearing potential of the risks of pregnancy with concomitant thyroid disease. Advise women of childbearing potential to discuss pregnancy planning with their doctor. </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<p class="First"><span class="Underline">Infusion Reactions</span></p>
<ul>
<li>Advise patients that infusion reactions can occur after they leave the infusion center <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>Instruct the patient to remain at the infusion center for 2 hours after each LEMTRADA infusion, or longer at the discretion of the physician. Advise patients that symptoms of infusion reactions may occur after they leave the infusion center and to report these symptoms to their doctor.</li>
<li>Advise patients to contact their healthcare provider promptly if they experience infusion reactions, which include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the mouth or throat, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, abnormal heart rate (fast, slow, or irregular), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<p class="First"><span class="Underline">Malignancies</span></p>
<ul>
<li>Advise patients that LEMTRADA may increase their risk of malignancies including thyroid cancer and melanoma <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. </li>
<li>Advise patients to report symptoms of thyroid cancer, including a new lump or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the neck, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the front of the neck, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span> or other voice changes that do not go away, trouble swallowing or breathing, or a constant <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> not due to a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>.</li>
<li>Advise patients that they should have baseline and yearly skin examinations.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.4"></a><p></p>
<p class="First"><span class="Underline">LEMTRADA REMS Program</span></p>
<ul class="Disc">
<li>LEMTRADA is available only through a restricted program called the LEMTRADA REMS Program <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>. Inform the patient of the following notable requirements:<ul>
<li>Patients and providers must be enrolled in the program.</li>
<li>Patients must comply with the ongoing monitoring requirements.</li>
<li>Patients must report any side effects or symptoms to their doctor.</li>
</ul>
</li>
<li>LEMTRADA is available only at certified infusion centers participating in the program. Therefore, provide patients with information on the LEMTRADA REMS Program in order to locate an infusion center.</li>
<li>Advise patients to read the LEMTRADA REMS material for patients, <span class="Italics">What You Need to Know About LEMTRADA Treatment: A Patient Guide</span> and <span class="Italics">What You Need to Know About LEMTRADA Treatment and Infusion Reactions: A Patient Guide</span>.</li>
<li>Instruct patients to carry the LEMTRADA REMS Patient Safety Information Card with them in case of an emergency.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span></p>
<ul>
<li>Advise patients to contact their healthcare provider if they develop symptoms of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>. </li>
<li>Advise patients to complete any necessary immunizations at least 6 weeks prior to treatment with LEMTRADA <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. Advise patients that they should talk to their healthcare provider before taking any vaccine after recent treatment with LEMTRADA <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>. </li>
<li>Advise patients to take their prescribed medication for herpes prophylaxis as directed by their healthcare provider <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>. </li>
<li>Advise patients that yearly HPV screening is recommended <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</li>
<li>Advise patients to avoid or adequately heat foods that are potential sources of <span class="Italics">Listeria monocytogenes</span> if they have had a recent course of LEMTRADA. The duration of increased risk for listeria <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after LEMTRADA administration is not known <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.6"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></span></p>
<ul><li>Advise patients that <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> has been reported in patients treated with LEMTRADA <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>. Advise patients to report symptoms of <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or tightness, and <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.7"></a><p></p>
<p class="First"><span class="Underline">Concomitant Use of Campath</span></p>
<ul><li>Advise patients that alemtuzumab is the same drug as Campath for use in B-CLL. Patients should inform their healthcare provider if they have taken Campath <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Manufactured and distributed by:</p>
<p>Genzyme Corporation<br>500 Kendall Street<br>Cambridge, MA 02142</p>
<p>US License Number: 1596</p>
<p>LEMTRADA is a trademark of Genzyme Corporation.</p>
<p>CAMPATH is a registered trademark of Genzyme Corporation.</p>
<p>© 2014 Genzyme Corporation.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="medguide"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">LEMTRADA™ (lem-TRA-da) <br>(alemtuzumab) <br>Injection for intravenous infusion</span></p>
<p>Read this Medication Guide before you start receiving LEMTRADA and before you begin each treatment course. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. </p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about LEMTRADA?</span></p>
<p><span class="Bold">LEMTRADA can cause serious side effects, including:</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Serious autoimmune problems. </span>Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity) which can be serious and may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Serious autoimmune problems may include: <dl>
<dt>•</dt>
<dd>
<span class="Bold">immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> (ITP).</span> LEMTRADA may cause the number of platelets in your blood to be reduced (ITP). ITP can cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that, if not treated, may cause life-threatening problems. Call your healthcare provider right away if you have any of the following symptoms:<dl>
<dt>○</dt>
<dd>easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from a cut that is hard to stop</dd>
<dt>○</dt>
<dd>heavier menstrual periods than normal</dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from your gums or nose that is new or takes longer than usual to stop</dd>
<dt>○</dt>
<dd>small, scattered spots on your skin that are red, pink, or purple </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">kidney problems.</span> LEMTRADA may cause a serious kidney problem, called anti-glomerular basement membrane disease. If this happens and you do not get treated, anti-glomerular basement membrane disease can lead to severe kidney damage, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> that needs dialysis, a kidney transplant, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your healthcare provider right away if you have any of the following symptoms: <dl class="Circle">
<dt>○</dt>
<dd>blood in the urine (red or tea-colored urine)</dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your legs or feet</dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood</dd>
</dl>
</dd>
</dl>
<br>Side effects may happen while you receive LEMTRADA and for 4 years after you stop receiving LEMTRADA. Your healthcare provider will order blood and urine tests before you receive, while you are receiving, and every month for 4 years after you receive your last LEMTRADA infusion. You may need to continue these blood and urine tests after 4 years if you have any autoimmune signs or symptoms. The blood and urine tests will help your healthcare provider watch for signs and symptoms of serious autoimmune problems. <br>It is important to have your blood and urine tested, even if you are feeling well and do not have any symptoms from LEMTRADA and your <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. This may help your healthcare provider find any problems early and will increase your chances of getting better. </dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Serious infusion reactions. </span> LEMTRADA can cause serious infusion reactions that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Serious infusion reactions may happen while you receive, or up to 24 hours or longer after you receive LEMTRADA. <br>You will receive your infusion at a healthcare facility with equipment and staff trained to manage infusion reactions. You will be watched while you receive and for 2 hours after you receive LEMTRADA. <span class="Bold">It is important</span> that you stay at the infusion center for <span class="Bold">2</span> hours after your infusion is finished or longer if your healthcare provider decides you need to stay longer. If a serious infusion reaction happens while you are receiving LEMTRADA, your infusion may be stopped. <br>Tell your healthcare provider right away if you have any of the following symptoms of a serious infusion reaction during the infusion, and after you have left the healthcare facility:<dl class="Circle">
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your mouth or throat</dd>
<dt>○</dt>
<dd>trouble breathing</dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>○</dt>
<dd>fast, slow, or irregular heart beat</dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></dd>
<dt>○</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></dd>
</dl>To lower your chances of getting a serious infusion reaction, your healthcare provider will give you a medicine called corticosteroids before your first 3 infusions of a treatment course. You may also be given other medicines before or after the infusion to try reduce your chances of these reactions or to treat them after they happen.</dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">Certain cancers. </span>Receiving LEMTRADA may increase your chance of getting some kinds of cancers, including thyroid cancer, skin cancer (melanoma), and blood cancers called <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. Call your healthcare provider if you have the following symptoms that may be a sign of thyroid cancer:<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li>new lump</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your neck</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the front of your neck</li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span> or other voice changes that do not go away</li>
<li>trouble swallowing or breathing</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> that is not caused by a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span></li>
</ul></td>
</tr></tbody>
</table>
</dd>
</dl>
<p>You should have your skin checked before you start receiving LEMTRADA and each year while you are receiving treatment to monitor symptoms of skin cancer.</p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Because of your risk of autoimmunity, infusion reactions and the risk of some kinds of cancers, LEMTRADA is only available through a restricted program called the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program.</span> Call 1-855-676-6326 to enroll in the LEMTRADA REMS Program.</dd>
<dt>•</dt>
<dd>You and your healthcare provider must be enrolled in the LEMTRADA REMS Program.</dd>
<dt>•</dt>
<dd>LEMTRADA can only be given at a certified healthcare facility that participates in the LEMTRADA REMS Program. Your healthcare provider can give you information on how to find a certified healthcare facility.</dd>
<dt>•</dt>
<dd>Read the LEMTRADA REMS "What You Need to Know About LEMTRADA Treatment: A Patient Guide" and "What you Need to Know About LEMTRADA Treatment and Infusion Reactions: A Patient Guide" after you are enrolled in the program.</dd>
<dt>•</dt>
<dd>Carry your LEMTRADA REMS Patient Safety Information Card with you in case of an emergency.</dd>
</dl>
<p><span class="Bold">What is LEMTRADA?</span></p>
<p>LEMTRADA is a prescription medicine used to treat adults with relapsing forms of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS). Because of its risks, LEMTRADA is generally used in people who have tried 2 or more MS medicines that have not worked well enough. It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.</p>
<p><span class="Bold">Who should not receive LEMTRADA?</span></p>
<p><span class="Bold"> Do not receive LEMTRADA if you</span> are infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV).</p>
<p><span class="Bold">What should I tell my healthcare provider before receiving LEMTRADA?</span></p>
<p>Before receiving LEMTRADA, tell your healthcare provider if you:</p>
<ul>
<li>are taking a medicine called Campath<span class="Sup">®</span>. Alemtuzumab the active ingredient in LEMTRADA is the same drug as Campath.</li>
<li>have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have thyroid problems</li>
<li>have kidney problems</li>
<li>have a recent history of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>have HIV</li>
<li>have received a live vaccine in the past 6 weeks before receiving LEMTRADA or plan to receive any live vaccines. Ask your healthcare provider if you are not sure if your vaccine is a live vaccine.</li>
<li>are pregnant or plan to become pregnant. LEMTRADA may harm your unborn baby. You should use birth control while receiving LEMTRADA and for 4 months after your course of treatment.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if LEMTRADA passes into your breast milk. You and your healthcare provider should decide if you should receive LEMTRADA or breastfeed. You should not do both.  </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </p>
<p>LEMTRADA and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take medicines that increase your chance of getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including medicines used to treat cancer or to control your immune system.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How will I receive LEMTRADA?</span></p>
<ul>
<li>LEMTRADA is given through a needle placed in your vein (IV infusion). </li>
<li>It takes about 4 hours to receive a full dose of LEMTRADA each day. </li>
<li>You will receive LEMTRADA over 2 treatment courses. </li>
<li>You will receive LEMTRADA for 5 days in a row (consecutive) for the first treatment course and then for 3 days in a row (consecutive) about 1 year later for your second treatment course.   </li>
</ul>
<p><span class="Bold">What are the possible side effects of LEMTRADA?</span></p>
<p><span class="Bold">LEMTRADA may cause serious side effects including: </span></p>
<ul>
<li>See <span class="Bold">"<a href="#important">What is the most important information I should know about LEMTRADA?</a>"</span>
</li>
<li>
<span class="Bold">thyroid problems.</span> Some people who receive LEMTRADA may get thyroid problems including an overactive thyroid (<span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>) or an underactive thyroid (<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>). Your healthcare provider will do blood tests to check how your thyroid is working. Call your healthcare provider if you have any of the symptoms of thyroid problems.<br>Symptoms of <span class="Bold"><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span></span> may include:<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li>excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></li>
<li>fast heartbeat</li>
</ul></td>
</tr></tbody>
</table>Symptoms of <span class="Bold"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></span> may include:<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li>unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span> </li>
</ul></td>
<td align="left"><ul class="Circle">
<li>worsening <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold">low blood counts (<span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>).</span> LEMTRADA may cause a decrease in some types of blood cells. Some people with these low blood counts have increased <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> may include:<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li>yellowing of the skin or whites of  eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
</ul></td>
<td align="left"><ul class="Circle">
<li>dark urine</li>
<li>fast heartbeat</li>
</ul></td>
</tr></tbody>
</table>Your healthcare provider will do blood tests to check for <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>. Call your healthcare provider right away if you have symptoms listed above.</li>
<li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>LEMTRADA may cause you to have serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> while you receive and after receiving a treatment course. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may include:<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infections</span>.</span> Some people taking LEMTRADA have an increased chance of getting <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infections</span>. Your healthcare provider will prescribe medicines to reduce your chances of getting these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Take these medicines exactly as your healthcare provider tells you to.</li>
<li>
<span class="Bold">human <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> virus (HPV).</span> Females have an increased chance of getting a cervical HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If you are a female, you should have an HPV screening each year.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. </span>Your healthcare provider should check you for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> before you receive LEMTRADA.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. </span></li>
<li>
<span class="Bold">listeria.</span> People who receive LEMTRADA have an increased chance of getting an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by the bacteria, listeria. Avoid foods that may be a source for listeria (for example, deli meat, unpasteurized milk and cheese products, or undercooked meat, seafood or poultry) or make sure that the food you eat which may contain listeria is heated well if you receive treatment with LEMTRADA.</li>
</ul>Call your healthcare provider right away if you have symptoms of a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span>. You may need to go to the hospital for treatment if you get a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. It is important to tell the healthcare providers that you have received LEMTRADA.<br>Talk to your healthcare provider before you get vaccinations after receiving LEMTRADA. Certain vaccinations may increase your chances of getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>  of lung tissue (<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>).</span> Some people have  had <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lung tissue while receiving LEMTRADA. Call your  healthcare provider right away if you have the following symptoms:<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or tightness</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood</li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<p>The most common side effects of LEMTRADA include:</p>
<table class="Noautorules" width="80%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
</colgroup>
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>thyroid problems</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your nose and throat (<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>       </li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
<li>feeling tired</li>
<li>trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes viral infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms or legs</li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012068" conceptname="Sore mouth">mouth pain</span> or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>sudden <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in face, neck, or chest</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul></td>
</tr></tbody>
</table>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of LEMTRADA. For more information, ask your healthcare provider or pharmacist. </p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General information about the safe and effective use of LEMTRADA.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LEMTRADA for a condition for which it was not prescribed. Do not give LEMTRADA to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about LEMTRADA. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about LEMTRADA that is written for health professionals.</p>
<p>For more information, go to <span class="Underline">www.LemtradaREMS.com</span> or call Genzyme at 1-855-676-6326. </p>
<p><span class="Bold">What are the ingredients in LEMTRADA?</span></p>
<p><span class="Bold">Active ingredient:</span> alemtuzumab</p>
<p><span class="Bold">Inactive ingredients:</span> sodium chloride, dibasic sodium phosphate, potassium chloride, potassium dihydrogen phosphate, polysorbate 80, disodium edetate dihydrate, and water for injection.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Manufactured and distributed by: </span></p>
<p>Genzyme Corporation</p>
<p>500 Kendall Street</p>
<p>Cambridge, MA 02142</p>
<p>US License Number: 1596</p>
<p>LEMTRADA is a trademark of Genzyme Corporation.</p>
<p>CAMPATH is a registered trademark of Genzyme Corporation.</p>
<p>©2014 Genzyme Corporation. All rights reserved.</p>
<p>Issued: November 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12 mg/1.2 mL Vial Carton</h1>
<p class="First">NDC 58468-0200-1</p>
<p><span class="Bold">LEMTRADA</span>™ <br>(alemtuzumab) <br>injection</p>
<p><span class="Bold">12 mg/1.2 mL</span><br>(10 mg/mL)</p>
<p>For Intravenous Infusion Only <br>Dilute before <br>Intravenous Infusion <br>Single-Dose Vial, <br>Discard Unused Portion</p>
<p>Rx only</p>
<p><span class="Bold">Dispense the enclosed <br>Medication Guide to each <br>patient.</span></p>
<div class="Figure"><img alt="Principal Display Panel - 12 mg/1.2 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269&amp;name=lemtrada-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEMTRADA 		
					</strong><br><span class="contentTableReg">alemtuzumab injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58468-0200</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALEMTUZUMAB</strong> (alemtuzumab) </td>
<td class="formItem">ALEMTUZUMAB</td>
<td class="formItem">12 mg  in 1.2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.0224 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem">0.24 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">0.24 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9.6 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">1.38 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem">0.12 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58468-0200-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103948</td>
<td class="formItem">11/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genzyme Corporation
							(025322157)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH &amp; Co. KG (BI Pharma)</td>
<td class="formItem"></td>
<td class="formItem">340700520</td>
<td class="formItem">ANALYSIS(58468-0200), MANUFACTURE(58468-0200), API MANUFACTURE(58468-0200)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Ireland Ltd</td>
<td class="formItem"></td>
<td class="formItem">985127419</td>
<td class="formItem">MANUFACTURE(58468-0200)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Limited</td>
<td class="formItem"></td>
<td class="formItem">229522842</td>
<td class="formItem">MANUFACTURE(58468-0200)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>26ec6adb-b2a1-4480-80f6-2d81311ddb5f</div>
<div>Set id: 6236b0bc-82e9-4447-9a78-f57d94770269</div>
<div>Version: 1</div>
<div>Effective Time: 20141113</div>
</div>
</div> <div class="DistributorName">Genzyme Corporation</div></p>
</body></html>
